<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950842</url>
  </required_header>
  <id_info>
    <org_study_id>jRCT2073200067</org_study_id>
    <nct_id>NCT04950842</nct_id>
  </id_info>
  <brief_title>Induction of Transplant Tolerance in LDLT Via iTS</brief_title>
  <official_title>Phase I/II Study to Evaluate the Safety and Efficacy of JB-101(Induced T Cell With Suppressing Functions), to Induce Operational Tolerance in Living Donor Liver Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juntendo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Junten Bio Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Juntendo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to examine the immunotolerance-inducing ability&#xD;
      (effectiveness) of induced inhibitory T cells JB-101 in patients with living-donor liver&#xD;
      transplantation using &quot;whether or not operational tolerance is achieved&quot; as an index.&#xD;
&#xD;
      And the safety of JB-101 will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a phase I / II, open-label, single-arm, multicenter clinical trial of JB-101,&#xD;
      an inducible inhibitory T cell, in patients with end-stage liver failure who undergo&#xD;
      living-donor liver transplantation.&#xD;
&#xD;
      The primary endpoint of efficacy is withdrawal from immunosuppressant by 78 weeks (up to 91&#xD;
      weeks) after liver transplantation, and then &quot;whether or not operational tolerance is&#xD;
      achieved&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of operational tolerance</measure>
    <time_frame>immunosuppressive drug cessation was maintained for at least 12 months</time_frame>
    <description>Achievement of &quot;Operational Tolerance&quot; defined as no biopsy proven rejection diagnosed by Banff criteria for more than 52 weeks after withdrawal of immunosuppressive drugs post transplant</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Living-donor Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>JB-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>induced T cell with suppressive function</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JB-101</intervention_name>
    <description>induced T cell with suppressive function</description>
    <arm_group_label>JB-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria：&#xD;
&#xD;
        Patients with end-stage liver failure undergoing living-donor liver transplantation.&#xD;
&#xD;
        Subjects who are healthy physically and psychologically and willing to donate organs&#xD;
        voluntarily.&#xD;
&#xD;
        Relative within the second degree of relationship or partner. (Acceptable degree conforms&#xD;
        eligibility criteria of the institution.)&#xD;
&#xD;
        Exclusion Criteria：&#xD;
&#xD;
        Patients who have clinical findings of active infection.&#xD;
&#xD;
        Patients with advanced heart disease, fulminant hepatitis in liver failure, renal disease,&#xD;
        malignant tumors and complications of immunodeficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koichiro Uchida, M.D.,Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Juntendo University Advanced Research Institute for Health Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Saori Hirota</last_name>
    <phone>＋81-70-1000-8906</phone>
    <email>s.hirota.zk@juntendo.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatsunori Toyonaga</last_name>
    <phone>+81-70-4193-4337</phone>
    <email>toyonaga@juntenbio.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hiroto Egawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hiroshima University Hospital</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hideki Ohdan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susumu Eguchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Todo S, Yamashita K, Goto R, Zaitsu M, Nagatsu A, Oura T, Watanabe M, Aoyagi T, Suzuki T, Shimamura T, Kamiyama T, Sato N, Sugita J, Hatanaka K, Bashuda H, Habu S, Demetris AJ, Okumura K. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology. 2016 Aug;64(2):632-43. doi: 10.1002/hep.28459. Epub 2016 Mar 10.</citation>
    <PMID>26773713</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Juntendo University</investigator_affiliation>
    <investigator_full_name>Koichiro Uchida</investigator_full_name>
    <investigator_title>Associate Professpr</investigator_title>
  </responsible_party>
  <keyword>living-donor liver transplantation</keyword>
  <keyword>immunotolerance</keyword>
  <keyword>operational tolerance</keyword>
  <keyword>cell therapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

